Mantle cell lymphoma refractory – Diagnostics – Overview of Information and Clinical Research

Diagnosing relapsed or refractory mantle cell lymphoma requires careful evaluation to determine the best treatment path forward. When this rare blood cancer returns after treatment or stops responding to therapy, doctors rely on a combination of familiar tests and advanced assessments to understand the extent of disease and guide treatment decisions, including enrollment in clinical trials that may offer new hope.

Introduction: Who Needs Diagnostic Testing

Patients with mantle cell lymphoma need diagnostic testing when their disease comes back after a period of improvement, known as remission, or when the cancer stops responding to treatment altogether. The term relapsed describes a situation where the lymphoma reappears or begins growing again after it had previously gotten better with treatment. On the other hand, refractory disease means that the lymphoma does not respond to treatment from the start, meaning the cancer cells continue to multiply despite therapy, or the response to treatment is very brief and does not last long.^[1]

Anyone who previously received treatment for mantle cell lymphoma should seek medical evaluation if they notice certain warning signs. These include swollen lymph nodes that can be felt as lumps in the neck, armpits, or groin. Other symptoms that warrant attention include unexplained fever, drenching night sweats that require changing clothes or sheets, weight loss without trying, and persistent fatigue that interferes with daily activities.^[5] Because most patients with mantle cell lymphoma tend to experience relapse after their initial treatment, regular monitoring and prompt evaluation of new symptoms is extremely important.^[1]

The timing of when symptoms appear matters greatly in determining what happens next. Some patients may notice changes within months of completing treatment, while others may enjoy several years without disease activity before symptoms return. Understanding when the relapse occurs helps doctors decide whether immediate treatment is necessary or if careful observation might be appropriate. For patients with slow-growing disease that causes no symptoms and involves only a small amount of cancer, doctors may recommend watchful waiting rather than starting treatment right away.^[17]

⚠️ Important

Several factors influence what type of diagnostic testing a patient needs and when treatment should begin. These include how quickly the disease came back after the last treatment, the patient’s age and overall health, how much cancer is present in the body, and which treatments have already been tried. The decision to pursue testing and treatment is highly personalized and requires thoughtful discussion between patients and their healthcare team.^[1]

Classic Diagnostic Methods

When doctors suspect that mantle cell lymphoma has returned or stopped responding to treatment, they begin with a thorough physical examination. This examination focuses on checking for swollen lymph nodes in the neck, underarms, and groin areas. The doctor also feels the abdomen to detect whether the spleen or liver has become enlarged, which can indicate that lymphoma cells have spread to these organs.^[13] Although a physical exam provides important clues, it cannot definitively confirm whether lymphoma is present or determine its extent throughout the body.

Blood tests play a central role in evaluating relapsed or refractory mantle cell lymphoma. These tests can sometimes reveal the presence of lymphoma cells circulating in the bloodstream. Additionally, blood tests measure levels of certain substances that may be elevated when lymphoma is active. One particularly important measurement is lactate dehydrogenase, or LDH, an enzyme that is often higher in people with lymphoma. Blood tests also provide information about overall health, including how well the kidneys and liver are functioning, and whether blood cell counts are normal or affected by the disease.^[13]

Imaging tests create detailed pictures of the inside of the body, allowing doctors to see where lymphoma is located and how much disease is present. Computed tomography, or CT scans, use special x-ray equipment to produce cross-sectional images of lymph nodes and organs. Positron emission tomography, known as PET scans, go a step further by showing not just the structure of tissues but also their metabolic activity, helping distinguish active cancer from scar tissue or inactive disease. Often, PET and CT scans are combined into a single test called a PET/CT scan, which provides both anatomical and functional information in one examination.^[13]

A lymph node biopsy remains the gold standard for confirming that mantle cell lymphoma has returned. During this procedure, a doctor removes all or part of a swollen lymph node so that the tissue can be examined in a laboratory. Pathologists study the tissue under a microscope to look for lymphoma cells and perform specialized tests to identify specific characteristics of the cancer. These tests can show whether the cells have certain proteins on their surface, such as CD5 and CD20, and whether they overproduce cyclin D1, a protein typically found in mantle cell lymphoma due to a chromosomal change.^[13]

Bone marrow aspiration and biopsy are procedures used to collect samples from the bone marrow, the soft tissue inside bones where blood cells are made. A doctor inserts a needle, usually into the hip bone, to withdraw liquid bone marrow (aspiration) and a small piece of solid bone marrow tissue (biopsy). These samples go to a laboratory where technicians examine them under a microscope to determine whether lymphoma cells have spread to the bone marrow. This information helps doctors understand how widespread the disease is and plan appropriate treatment.^[13]

Some patients may need additional specialized tests depending on their symptoms and physical exam findings. A colonoscopy involves inserting a flexible tube with a camera through the rectum to examine the inside of the colon and large intestine. This test is particularly important in mantle cell lymphoma because the gastrointestinal tract is a common site where this cancer can appear, sometimes causing the first symptoms that bring patients to medical attention.^[4]^[8] The doctor can take small tissue samples, called biopsies, from any suspicious areas seen during the colonoscopy for laboratory analysis.

Laboratory analysis of collected tissue samples provides crucial details about the lymphoma. Scientists perform tests to identify specific genetic changes within the cancer cells. The most common abnormality in mantle cell lymphoma is a translocation between chromosomes 11 and 14, written as t(11;14)(q13;q32), which causes cells to produce too much cyclin D1 protein. More than 95 percent of mantle cell lymphoma cases show this chromosomal change. Testing also reveals whether the cancer cells have specific proteins on their surface, such as being positive for CD5 and CD20 while negative for CD10 and having low or negative CD23.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments or combinations of treatments for relapsed or refractory mantle cell lymphoma. To participate in these research studies, patients must meet specific criteria that are carefully defined in each trial’s enrollment requirements. Diagnostic tests help determine whether a patient is eligible for a particular trial and establish baseline measurements that researchers will use to track how well the experimental treatment works.

Most clinical trials for relapsed or refractory mantle cell lymphoma require confirmation that the disease has either come back after previous treatment or did not respond adequately to prior therapy. This confirmation typically requires a recent biopsy showing active lymphoma cells. The biopsy must demonstrate the characteristic features of mantle cell lymphoma, including the presence of the t(11;14) chromosomal translocation and overexpression of cyclin D1 protein, or in rare cases, other related genetic changes.^[4] Having this documentation ensures that trial participants truly have the disease being studied.

Imaging studies form another essential component of clinical trial eligibility assessment. Before enrolling in a trial, patients usually undergo PET/CT scans to measure the size and location of all areas affected by lymphoma throughout the body. These scans create a starting point, or baseline, against which doctors can compare later scans to determine whether the experimental treatment is shrinking the cancer. Researchers often use specific criteria to define whether lymphoma has responded to treatment, such as whether tumors have gotten smaller, stayed the same size, or continued to grow.^[7]

Blood tests serve multiple purposes in qualifying patients for clinical trials. Researchers need to verify that patients have adequate organ function before exposing them to experimental treatments that might place additional stress on the kidneys, liver, or bone marrow. Blood tests measure levels of substances that indicate how well these organs are working. Additionally, some trials have specific requirements regarding blood cell counts, requiring that patients have sufficient numbers of red blood cells, white blood cells, and platelets to safely tolerate the study treatment.^[8]

Bone marrow examination may be required for some clinical trials, particularly those testing treatments that work differently depending on whether lymphoma has spread to the bone marrow. A bone marrow biopsy performed before starting the trial establishes whether marrow involvement is present and provides another way to measure treatment response during the study. Some trials specifically enroll patients with bone marrow disease, while others may exclude such patients, making this test crucial for determining eligibility.^[4]

Performance status assessment evaluates a patient’s overall physical condition and ability to carry out daily activities. Doctors use standardized scoring systems to rate how well patients can care for themselves and perform routine tasks. This assessment helps researchers ensure that study participants are healthy enough to tolerate experimental treatments and participate fully in the trial’s requirements, which may include frequent visits, additional testing, and potential side effects. The ECOG performance status scale is one commonly used tool that rates patients from 0 (fully active) to 4 (completely disabled).^[8]

Documentation of previous treatments is critical for clinical trial enrollment. Researchers need detailed records showing exactly what treatments a patient has received, how long each treatment lasted, and how well the lymphoma responded. This information determines whether patients meet criteria such as “relapsed after at least one prior therapy” or “refractory to BTK inhibitors.” Many trials specifically target patients whose disease has progressed after certain types of treatment, making this treatment history essential for determining eligibility.^[7]^[9]

⚠️ Important

Some clinical trials test treatments specifically designed for patients whose disease has stopped responding to drugs called covalent Bruton’s tyrosine kinase inhibitors, or cBTKi for short. These trials may require genetic testing of the lymphoma cells to understand why resistance to these drugs developed. Understanding resistance mechanisms helps researchers match patients with treatments most likely to help them and advances scientific knowledge about how to overcome treatment resistance.^[7]

Certain trials investigating immune-based therapies, such as CAR T-cell therapy or bispecific antibodies, may require additional specialized testing. These might include detailed immune system evaluations to ensure patients can mount appropriate immune responses, tests for active infections that could complicate immune therapy, or assessments of whether patients have received certain vaccines. Some immune therapies work by targeting specific proteins on the surface of lymphoma cells, so testing may confirm that a patient’s cancer cells express the right target proteins for the experimental treatment being studied.^[7]^[9]

Prognosis and Survival Rate

Prognosis

The outlook for patients with relapsed or refractory mantle cell lymphoma varies considerably depending on several important factors. Patients with the indolent, or slower-growing, form of the disease who experience relapse often have a significantly better outlook, with some people living more than 15 years. This indolent version occurs in about 20 percent of all mantle cell lymphoma cases and is characterized by small lymph nodes, disease present mainly in the blood rather than lymph nodes, lack of fever or weight loss symptoms, and specific laboratory features.^[4]^[10]

Most patients, about 80 percent, present with the more aggressive form of mantle cell lymphoma. When this aggressive type relapses or becomes refractory, outcomes depend heavily on treatment history and how quickly the disease came back. For patients whose lymphoma returned after many years of remission, additional treatments may achieve another period of disease control. However, when disease progresses quickly or doesn’t respond to initial therapies, the situation becomes more challenging.^[4]^[10]

The development of targeted drugs called covalent BTK inhibitors has substantially improved outcomes for many patients with relapsed disease over the past decade. When used specifically at first relapse, these medications can control disease for a median of about 26 months. However, approximately one-third of patients do not respond to these drugs, and many patients who initially respond will see their disease progress within two years of starting treatment.^[7]^[12]

Several factors help predict outcomes for individual patients. The Mantle Cell Lymphoma International Prognostic Index, or MIPI, considers four elements: performance status (how well someone can carry out daily activities), white blood cell count, LDH enzyme level, and age. This scoring system divides patients into low-risk, intermediate-risk, and high-risk groups. Additional poor prognostic features include specific genetic changes such as TP53 mutations or deletions, complex chromosomal abnormalities, high levels of a protein called Ki-67, and a particularly aggressive cell appearance called blastoid or pleomorphic variant.^[8]^[9]

Survival Rate

Survival rates for relapsed or refractory mantle cell lymphoma have improved with newer treatments, but the disease remains challenging. Patients with aggressive mantle cell lymphoma who receive modern treatments have a median survival exceeding 8 to 10 years from initial diagnosis. However, once the disease relapses, survival depends on multiple factors including the timing of relapse and what treatments are available.^[4]^[10]

Before the development of BTK inhibitors, patients with relapsed or refractory disease had a median progression-free survival of only 4 to 9 months with conventional treatments. The introduction of ibrutinib, the first BTK inhibitor, improved median progression-free survival to 13 to 14.6 months. For patients specifically using these drugs at first relapse, the time before disease progression extended to approximately 26 months.^[9]^[12]

Unfortunately, outcomes after disease progression on BTK inhibitors remain poor. Historical data showed that patients whose disease became resistant to these drugs had a median life expectancy ranging between 2.9 and 8.4 months in various studies. This represents one of the most significant areas of unmet need in treating mantle cell lymphoma. However, newer treatment options, including CAR T-cell therapy, are showing promise for improving survival in this difficult situation.^[7]^[12]

For younger, medically fit patients with relapsed disease, stem cell transplantation offers the possibility of longer-term disease control. Patients who undergo this procedure after achieving a good response to treatment of their relapsed lymphoma may experience extended remissions. Long-term survival data from specialized centers shows that carefully selected patients can achieve durable disease control with this approach, though the procedure carries significant risks and is not suitable for all patients.^[1]^[11]

#1 Clinical Trials Search in Europe